<DOC>
	<DOCNO>NCT00002147</DOCNO>
	<brief_summary>To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) therapy Kaposi 's sarcoma patient remain treatment option DOX-SL patient participate another DOX-SL protocol continuation DOX-SL medically indicate . Also , evaluate safety efficacy DOX-SL patient Kaposi 's sarcoma previously receive systemic chemotherapy without anthracycline .</brief_summary>
	<brief_title>Use Stealth Liposomal Doxorubicin HCl ( DOX-SL ) Treatment Moderate Severe AIDS-Related Kaposi 's Sarcoma .</brief_title>
	<detailed_description>Patients receive DOX-SL every 3 week 20 cycle .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDSrelated Kaposi 's sarcoma require systemic chemotherapy . EITHER medical indication continuation DOXSL follow treatment another DOXSL protocol , OR remain treatment option DOXSL . Prior Medication : Allowed : Prior anthracyclines . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Cardiac ejection fraction &lt; 50 percent clinically significant cardiac disease . Eligibility Liposomal Technology comparative protocol . Concurrent Medication : Excluded : Other cytotoxic chemotherapy . Patients follow prior condition exclude : History idiosyncratic allergic reaction anthracyclines . Prior Medication : Excluded : Chemotherapy within past 3 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1996</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Drug Carriers</keyword>
</DOC>